Acción de Finasteride sobre el volumen prostático en caninos con hiperplasia prostática benigna

    January 2002 in “ El Servicio de Difusión de la Creación Intelectual (National University of La Plata) ”
    María Alejandra Stornelli, María Cecilia Stornelli, Raúl Ricardo Rodríguez, Carla Floriana Scodellaro, César A. Savignone
    TLDR Finasteride effectively reduces prostate size in dogs with benign prostatic hyperplasia at a low, safe dose.
    In this study, adult male dogs with varying degrees of benign prostatic hyperplasia were administered 0.1 mg/kg per day of Finasteride, a selective 5 α-reductase inhibitor, orally. The treatment significantly reduced prostate size as evaluated by ultrasound, without any associated toxic side effects. Notably, the dosage used was 10 times lower than that used in other studies, yet it achieved similar results. This lower dosage reduced treatment costs and maintained safety, suggesting that Finasteride could be an excellent long-term treatment option for benign prostatic hyperplasia.
    Discuss this study in the Community →